Is PTGX or PYPD more undervalued in 2026?

CirclFi compares Protagonist Therapeutics, Inc. (PTGX) and PolyPid Ltd. (PYPD) using 13 institutional-grade valuation models. PTGX has a Quality of Company score of 7.4/10 while PYPD scores 1.8/10.

Which is a better buy — PTGX or PYPD?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PTGX and PYPD valuations compare?

PTGX at $100.41 and PYPD at $4.76 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PTGX vs PYPD Valuation Comparison 2026 — Intrinsic Value Analysis

PTGX

Biotechnology

Protagonist Therapeutics, Inc.

Quality

7.4

out of 10

Value Trap

SAFE

Price

$100.41

Last close

Models

13/13

Active

PYPD

Biotechnology

PolyPid Ltd.

Quality

1.8

out of 10

Value Trap

—

Price

$4.76

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	PTGX Fair Value	PTGX Upside	PYPD Fair Value	PYPD Upside
Bayesian DCF	Intrinsic	$32.65	-67.5%	$1.26	-73.5%
Earnings Power Value	Intrinsic	$43.68	-56.3%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$5.17	-94.8%	$26.22	+450.9%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PTGX vs PYPD — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PTGX vs PYPD — Which Stock Is More Undervalued?

PTGX scores higher with a 7.4/10 quality rating vs PYPD's 1.8/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Protagonist Therapeutics, Inc. (PTGX) and PolyPid Ltd. (PYPD) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PTGX currently trades at $100.41 with a QOC of 7.4/10, while PYPD trades at $4.76 with a QOC of 1.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).